Treatment of Influenza A in Pregnant Women

Immediate Treatment Recommendations

The American College of Obstetricians and Gynecologists recommends antiviral treatment with oseltamivir 75 mg orally twice daily for 5 days for any pregnant woman with suspected or confirmed influenza A, regardless of trimester or vaccination status 1
Oseltamivir is the first-line antiviral agent for pregnant women with influenza A, with a standard adult dosing of 75 mg orally twice daily for 5 days 1
Zanamivir 10 mg (two 5 mg inhalations) twice daily for 5 days can be used if oseltamivir is contraindicated 1

Safety Profile in First Trimester

The Centers for Disease Control and Prevention (CDC) found no association between first trimester influenza vaccination and major congenital malformations in a 5-year retrospective cohort of over 10,000 women 1
A systematic review and meta-analysis of 15 studies showed no association between congenital defects and influenza vaccination in any trimester, including the first 1
The Advisory Committee on Immunization Practices (ACIP) guidelines have evolved to support the use of antiviral drugs during pregnancy, based on current evidence of safety and efficacy 2, 3, 4, 5, 6, 7

Clinical Rationale for Aggressive Treatment

Pregnant women are at higher risk for severe illness, pneumonia, ICU admission, and death compared to non-pregnant women 1
The relative risk for hospitalization increases from 1.4 during weeks 14-20 of gestation to 4.7 during weeks 37-42 1
Influenza infection during pregnancy is associated with increased odds of congenital anomalies, stillbirth, late pregnancy loss, preterm delivery, low birth weight, and small-for-gestational-age infants 1

Important Clinical Considerations

Difficulty breathing or chest pain requires urgent evaluation 1
Persistent high fever requires urgent evaluation 1
Decreased fetal movement requires urgent evaluation 1
Signs of preterm labor require urgent evaluation 1

Prevention for Future Pregnancies

The American College of Obstetricians and Gynecologists recommends that all pregnant women receive inactivated influenza vaccine (IIV) during any trimester, including the first trimester 1
Live attenuated influenza vaccine (LAIV) is contraindicated during pregnancy 1
Vaccination protects both mother and infant, with infants born to vaccinated mothers having up to 72% risk reduction for laboratory-confirmed influenza hospitalization in the first few months of life 1

Antiviral Treatment for Influenza in Pregnant Women

Treatment Options

Zanamivir 10 mg (two 5 mg inhalations) twice daily for 5 days can be used if oseltamivir is contraindicated or unavailable, and is approved for use during pregnancy, particularly for pregnant women in high-risk and moderate-risk exposure groups 8
The American College of Obstetricians and Gynecologists is not cited for a recommendation in this article, however, the CDC guidelines are often referenced in conjunction with this topic, and according to the MMWR Recommendations and Reports, both oseltamivir and zanamivir are FDA Pregnancy Category C, meaning no controlled clinical trials have been conducted in pregnant women 9, 10

Safety Profile in Pregnancy

No adverse effects have been reported among women who received oseltamivir during pregnancy or among infants born to such women, according to the MMWR Recommendations and Reports 9

Prophylaxis Dosing

Oseltamivir 75 mg once daily for post-exposure prophylaxis in pregnant women with high-risk or moderate-risk exposure, and should continue for 7-10 days after last known exposure, as recommended by guidelines similar to those from the Lancet Infectious Diseases 8

Oseltamivir Use in Pregnancy

Safety Profile in Pregnancy

The FDA classifies oseltamivir as Pregnancy Category C, but extensive post-marketing surveillance and observational data demonstrate reassuring safety outcomes, according to the MMWR Recommendations and Reports 11
Only 1% of patients discontinue treatment due to gastrointestinal side effects, as reported by the MMWR Recommendations and Reports 11

Oseltamivir Treatment for Pregnant Women with Influenza

Immediate Treatment Recommendation

The Centers for Disease Control and Prevention recommends that all pregnant women with suspected or confirmed influenza should receive oseltamivir 75 mg orally twice daily for 5 days, starting immediately without waiting for laboratory confirmation, with treatment beginning as soon as possible after symptom onset, ideally within 48 hours 12
Pregnancy is explicitly not a contraindication to oseltamivir use, and the same dosing regimen used in non-pregnant adults applies to pregnant women 12

Safety Profile in Pregnancy

No adverse effects have been reported among women who received oseltamivir during pregnancy or their infants, according to the Morbidity and Mortality Weekly Report 12

Alternative Treatment Option

Zanamivir 10 mg (two 5 mg inhalations) twice daily for 5 days can be used if oseltamivir is contraindicated or unavailable, although oseltamivir remains the preferred first-line agent 12
Zanamivir has limited systemic absorption and inhaled administration carries potential respiratory complications, particularly in women with underlying respiratory conditions 12

Post-Exposure Prophylaxis

For pregnant women exposed to influenza, oseltamivir 75 mg once daily for 7-10 days after last exposure is recommended for high-risk exposure 13
For moderate-risk exposure, oseltamivir 75 mg once daily for 7-10 days after last exposure is recommended 13, 14

Managing Common Side Effects

Taking oseltamivir with food significantly reduces nausea and vomiting, according to the Morbidity and Mortality Weekly Report 12

Important Clinical Caveat

Fever itself poses risks to fetal development, so treating influenza with oseltamivir may actually reduce fetal risk by shortening illness duration and reducing fever, and acetaminophen should be used concurrently for fever management 12

Oseltamivir Use in Pregnant Women

Treatment and Prophylaxis

For pregnant women exposed to influenza, oseltamivir 75 mg once daily for 7-10 days after last exposure is recommended for high-risk and moderate-risk exposure, as stated by The Lancet Infectious Diseases 15

Clinical Rationale

Influenza infection during pregnancy is associated with increased odds of congenital anomalies, stillbirth, late pregnancy loss, preterm delivery, low birth weight, and small-for-gestational-age infants, highlighting the need for aggressive treatment 15

Treatment for Influenza in Pregnancy

Alternative Treatment Option

Zanamivir 10 mg (two 5 mg inhalations) twice daily for 5 days can be used if oseltamivir is contraindicated or unavailable, according to the American College of Obstetricians and Gynecologists 16
Zanamivir is generally not recommended for patients with underlying airway disease due to risk of serious adverse events, as stated by the American Academy of Family Physicians 17

Clinical Rationale for Aggressive Treatment

Pregnant women face disproportionately high death rates during influenza pandemics and are 7.2% more likely to be hospitalized than non-pregnant women, according to the American College of Obstetricians and Gynecologists 16

Vaccination

Live attenuated influenza vaccine (LAIV, intranasal) is contraindicated during pregnancy, but inactivated influenza vaccine should be administered during any trimester for future protection, as recommended by the American College of Obstetricians and Gynecologists 16

Influenza Vaccination and Antiviral Management in Pregnancy

Vaccination Recommendations

Clinical Risks of Influenza in Pregnancy

Safety Profile of Inactivated Influenza Vaccine

Neonatal Benefits of Maternal Vaccination

Physiologic Vulnerability of Pregnant Women

Oseltamivir Use in Pregnancy: Safety, Efficacy, and Guideline Evolution

Safety Evidence from Real‑World Surveillance

The Centers for Disease Control and Prevention (CDC) – MMWR reports that extensive post‑marketing surveillance has found no adverse maternal or infant outcomes linked to oseltamivir exposure during pregnancy. [22][23]
CDC – MMWR data show that the rate of major birth defects among oseltamivir‑exposed pregnancies (≈ 6.7 %) is comparable to that of unexposed pregnancies (≈ 7.9 %), indicating no increased teratogenic risk. [22][23]

Common Adverse Effects and Mitigation

In pregnant women treated with oseltamivir, nausea occurs in ~10 % and vomiting in ~9 % of patients; these gastrointestinal symptoms are significantly reduced when the drug is taken with food. [22][23]

Historical Guideline Language and Current Consensus

The Advisory Committee on Immunization Practices (ACIP) prior to 2008 advised that oseltamivir “should be used during pregnancy only if the potential benefit justifies the potential risk,” reflecting the lack of controlled trial data at that time. 24
Subsequent CDC – MMWR evidence (2007‑2008) and accumulated real‑world experience have shifted consensus: pregnancy is not a contraindication to oseltamivir, and the drug is recommended when influenza is suspected or confirmed. [22][23]24

Zanamivir Use and Renal Dose Adjustments in Pregnancy

Zanamivir Limitations

In pregnant women who cannot receive oseltamivir (e.g., documented hypersensitivity), inhaled zanamivir 10 mg twice daily for 5 days is an alternative, but its limited systemic absorption and the potential for respiratory complications—especially in patients with asthma or chronic obstructive pulmonary disease—make it generally unsuitable for individuals with underlying airway disease. 25

Renal Dose Adjustment for Oseltamivir

For pregnant patients with renal insufficiency (creatinine clearance 10–30 mL/min), the oseltamivir treatment regimen should be adjusted to 75 mg once daily for 5 days instead of the standard 75 mg twice daily dosing. 25